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Abstract
Head and neck squamous cell carcinoma (HNSCC) is a frequently fatal heterogeneous disease. Beyond the role of human
papilloma virus (HPV), no validated molecular characterization of the disease has been established. Using an integrated
genomic analysis and validation methodology we confirm four molecular classes of HNSCC (basal, mesenchymal, atypical,
and classical) consistent with signatures established for squamous carcinoma of the lung, including deregulation of the
KEAP1/NFE2L2 oxidative stress pathway, differential utilization of the lineage markers SOX2 and TP63, and preference for
the oncogenes PIK3CA and EGFR. For potential clinical use the signatures are complimentary to classification by HPV
infection status as well as the putative high risk marker CCND1 copy number gain. A molecular etiology for the subtypes is
suggested by statistically significant chromosomal gains and losses and differential cell of origin expression patterns. Model
systems representative of each of the four subtypes are also presented.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is
a heterogeneous disease that represents the seventh most
common form of cancer in the United States. Beyond the role
of human papilloma virus (HPV), no validated molecular
characterization of the disease has been established [1–4]. To
further characterize the diversity of HNSCC as well as other
tumors, our group and others have suggested gene expression
(GE) subtypes as a means to prioritize the dominant genomic
patterns within a specific tumor group [5–11]. Validated
subtypes based primarily on GE profiling of breast cancer,
glioblastoma, lung cancer, and others have garnered broad
interest [5–7,9–11]. Preliminary work has suggested that
clinically relevant subtypes are also found in head and neck
cancer [8], but the findings have not been replicated, no model
systems have been proposed, and the etiology of the subtypes is
obscure. In other tumor types the validation of molecular
signatures has been established by the following approach: (i)
the subtypes were shown to be statistically valid, (ii) genomic
alterations underlying the subtypes were documented, and (iii)
model systems representative of the expression subtypes were
identified. The current study was conceived to address each of
the points mentioned above. Because the goal of this study was
to detect gene expression patterns and underlying genomic
events that are present in HNSCC, the study design did not
incorporate any molecular subtypes that were defined a priori –
e.g. subtypes classified by HPV status.
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Results
Unsupervised Discovery of HNSCC Expression Subtypes
In order to address the question of whether statistically
significant gene expression subtypes can be detected in HNSCC,
we performed hierarchical clustering in an unsupervised and
unbiased manner using well-established and objective techniques
[7]. As in the prior work by Chung et al. [8], we documented the
presence of four gene expression subtypes. Gene expression
heatmaps (Figure 1A) and plots produced by ConsensusCluster-
Plus [12] (Figure S1 A – C) do not support the presence of
additional statistically significant clusters in this dataset. A
representative set of genes known or suspected to be relevant for
head and neck cancer is shown in Figure 1B, and test statistics for
the association of all genes in the dataset with tumor subtype are
provided in Table S1. SigClust [13] analysis showed that the p-
values for all of the pairwise comparisons of the expression
subtypes were significant at the.05 level after applying a Bonferroni
correction for multiple comparisons (Figure S1D). We refer to the
expression subtypes as basal (BA), mesenchymal (MS), atypical
(AT), and classical (CL) based on biological characteristics of genes
highly expressed in each subtype.
Clinical Characteristics
The clinical characteristics of the patients included in the
current study represent a broad cross section of patients with
HNSCC that is highly representative of the population seen in
a typical clinical practice (Table 1). There was no correlation of
tumor subtype with age, gender, race, alcohol use, pack years, or
tumor size. Tumor subtypes were statistically associated with site,
although all sites had tumors in each of the expression subtypes,
with one exception (hypopharynx showed no BA). Additionally, no
site contributed more than 58% of its samples to one expression
subtype. No expression subtype was made up of more than 68% of
tumors from a single site. Therefore, unlike other molecular
markers such as HPV or p16, we conclude that expression
subtypes captured a dimension of biology which was not limited to
a single anatomic site [14]. There were additional statistically
significant associations between tumor subtype and HPV status,
treatment, node status, and overall stage. It is notable that more
BA trended towards being well differentiated, whereas 13 of 16
poorly differentiated tumors were either MS or CL, although this
difference was not statistically significant.
Validation of Subtypes
We then turned our attention to the question of whether the
expression subtypes detected in the current dataset corresponded
to those previously reported by Chung et al. [8]. Wilkerson et al.
[7] presented a method for comparing gene expression patterns
found in expression subtypes across multiple studies. We use the
same procedure, which is described more fully in the Methods
section. Briefly, centroids of expression subtypes measure average
gene expression values, and subtypes with concordant expression
patterns produce centroids that are more highly correlated than
subtypes with discordant expression patterns. A clear correspon-
dence was observed (Figure 1C), with BA, MS, AT, and CL
Figure 1. Gene Expression Subtypes in Head and Neck Squamous Cell Carcinoma. Heatmaps of the expression values of the 840 classifier
genes (A) and select genes associated with HNSCC (B) for each of the expression subtypes. Validation heatmaps of the centroid-based distances
between the centroids of the expression subtypes in the current study and those from Chung et al. (C) and the LUSC subtypes of Wilkerson et al. (D).
doi:10.1371/journal.pone.0056823.g001
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Table 1. Clinical Data.
Total Basal Mesenchymal Atypical Classical p-Value
Num. Patients 138 44 33 32 29
Age (Years) .75
Median 57 60 57 56.5 58
Num. ,40 9 5 3 1 0
Sex .64
Female 43 14 13 8 8
Male 95 30 20 24 21
Race .34
Black 32 8 8 6 10
White 104 36 24 26 18
Alcohol Use .44
None/Light 86 26 24 20 16
Heavy 50 18 8 12 12
Smoking .11
Never/Light 27 13 6 6 2
Current/Former 109 30 26 26 27
Mean (Packyears) 36.0 36.7 33.1 30.1 45.0 .13
Differentiation .10
Well 26 14 5 3 4
Moderate 92 27 21 25 19
Poor 19 3 7 3 6
Tumor Site 1e-4*
Larynx 30 10 4 5 11
Oral Cavity 55 30 18 2 5
Oropharynx 34 3 5 20 6
Hypopharynx 13 0 2 5 6
Stage** .034*
I 10 2 4 0 4
II 14 8 1 2 3
III 28 8 8 4 8
IVa 77 26 16 22 13
IVb 6 0 3 3 0
IVc 10 0 0 1 0
Tumor Status .76
T0-T2 40 12 10 8 10
T3-T4 77 30 16 16 15
Node Status .0026
N0-N1 66 30 14 6 16
N2-N3 51 12 12 18 9
Treatment 4.5e-6
Primary Chemo/RT 62 11 13 26 12
Surgery 74 33 20 5 16
HPV Status .035
Negative 82 27 21 17 17
Positive 14 1 3 8 2
Chromosomal Instability Index .056 .052 .048 .036 .136 2.2e-4
Summaries of select clinical covariates in the HNSCC expression subtypes. P-values for categorical variables were computed using Fisher’s Exact Test or a Monte Carlo
version of Fisher’s Exact Test (p-values marked with *). P-values for continuous variables were computed using the Kruskal-Wallis test. **Stage I includes one patient that
was classified as stage 0.
doi:10.1371/journal.pone.0056823.t001
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demonstrating the same expression patterns as the Chung subtypes
1, 2, 3, and 4, respectively. Having discovered four subtypes using
independent and unbiased datasets and methods, we consider
these four expression subtypes to be validated.
Distinct Biological Processes and Similarities to Lung
Squamous Cell Carcinoma
The expression patterns found in the subtypes suggest the
presence of fundamental differences in the underlying biology of
the associated tumors (Table S2). Gene expression in BA showed
a strong similarity to the signature found in basal cells from the
human airway epithelium, including high expression of genes such
as COL17A1, which is associated with the extracellular matrix, the
growth factor and receptor TGFA and EGFR, and the transcription
factor TP63 [14]. Tumors in MS were exemplified by elevated
expression of genes associated with the epithelial-to-mesenchymal
transition (EMT), including the mesenchymal markers VIM and
DES, the transcription factor TWIST1, and the growth factor HGF
[15,16]. AT tumors had a strong HPV+ signature, as evidenced by
elevated expression of CDKN2A, LIG1, and the transcription factor
RPA2 [17]. Tumors in CL, the subtype with the heaviest smoking
history, showed high expression of genes associated with exposure
to cigarette smoke, including the xenobiotic metabolism genes
AKR1C1/3 and GPX2 [7,18,19] and the transcription factor
NFE2L2 [10].
Squamous cell carcinomas from different sites in the body share
a number of molecular characteristics – e.g. loss of chromosome
3p and gain of chromosome 3q [20,21] – so we hypothesized that
a correspondence between our expression subtypes and recently
reported lung squamous cell carcinoma (LUSC) expression
subtypes [7] would be observed. To investigate a broader
phenotype of squamous cell carcinomas of the upper aerodigestive
tract, we extended the centroid predictor methodology and
evaluated the correspondence of centroids from LUSC and
HNSCC (Figure 1D). Remarkably, a clear pattern of correlation
was observed in which the BA, MS, and CL subtypes of HNSCC
corresponded to the LUSC basal, secretory, and classical subtypes,
respectively, of Wilkerson et al. [7]. Examination of the TCGA
LUSC data [10] provided additional compelling evidence of the
underlying connections between the expression subtypes at the two
tumor sites (Figure S2). The correspondence between the basal
subtypes is notable because Wilkerson et al. [7] described time
course experiments involving cultured human bronchial epithelial
cells in which gene expression patterns at early time points showed
a strong resemblance to those seen in the basal subtype of LUSC.
Similarly, as shown in Table S3, we observed that the basal
subtype of HNSCC is most similar to the day 3 time point in the
time course data from the air liquid interface (ALI) model [22].
DNA Copy Analysis by Subtype
We then turned our attention to the genomic alterations of
HNSCC as measured by copy number (CN) arrays. First we
confirmed many regions previously reported as altered in
HNSCC, including gain of chromosomes 3q, 7p, and 11q
(statistically significant gains are seen in both 11q13 and 11q22)
and loss of chromosomes 3p, 9p, and 14q (Table S4 ). As has been
seen in other tumors [11], there are both concordant and
discordant patterns of copy number alteration in key regions of
the genome as a function of tumor subtype (Figure 2, Table S5 ).
For example, gains of 3q vary by expression subtype (p = .01),
whereas no significant CN differences between the subtypes were
detected in 11q13, which contains CCND1 (p = 1). The canonical
HNSCC 7p gain occurred in a region containing EGFR, but these
alterations were found in BA, MS, and CL, not AT (p= .01). CN
values in 3p were not significantly different across the subtypes
(p = .47). Losses of the 9p region that contains CDKN2A were
found in BA and CL only, and the CN differences were significant
(p = .01). Focal CN loss was found in 14q32 for MS, CL, and is
particularly pronounced in AT, but although this did not not reach
statistical significance. This region contains miR203, which is
notable because it targets DNp63 [23], one of six protein products
of TP63. Chromosomal instability also varied considerably by
subtype (p = 2.2e-4), as seen in Figure S3.
Copy Number Changes and Differential Expression of
Genes in Chromosome 3q by Expression Subtype
One of the quintessential genomic alterations associated with
squamous cell carcinomas is gain of 3q [20,21], and in the
previous section we noted that the CN values in this region varied
by expression subtype. Interestingly, there was a distinct differen-
tial proportional usage of the three genes typically discussed as the
targets of the amplicon: TP63, PIK3CA, and SOX2 (Figure 3). The
CL and AT subtypes demonstrated proportionally higher expres-
sion of SOX2 relative to MS and BA, which in fact appeared to
express less SOX2 than normal tonsil controls. By contrast, the BA
subtype expressed dramatically higher levels of TP63 than any
other group. Similarly, although the MS subtype exhibited copy
number gains in 3q, none of the putative target genes appeared to
be expressed at levels higher than normal tonsil. Kruskal-Wallis
tests showed that the expression of each of TP63, PIK3CA, and
SOX2 was associated with expression subtype after a Bonferroni
adjustment for multiple testing (Table S6 ). This observation raises
the possibility that the heterogeneity of HNSCC might in part be
explained by differential usage of the transcription factors (SOX2
and TP63) and oncogene (PIK3CA) in the 3q amplicon, which is
more complex than has been previously reported [24]. It also
suggests that differential usage of transcription factors and
oncogenes, promoted in part by distinct copy number alterations,
may contribute to the gene expression signatures that define the
expression subtypes.
Copy Number Events Involving Canonical Cancer Genes
Earlier we noted that the copy number values in gain and loss
regions were associated with expression subtype. Now we describe
similar findings that were obtained when gene-specific copy
number values for genes known to play a role in HNSCC –
CCND1, CDKN2A, and EGFR – were considered, not the broader
regions discussed above. In the above discussion we stated that
gains of 11q13 were not significantly different across the subtypes,
and Table 2 shows that similar results were found when attention
was restricted to gains of CCND1. In contrast, the frequency of
EGFR gains ranged from 0% in AT to 31% in CL (p= .069), while
the frequency of CDKN2A losses varied between 10% in MS to
63% in CL (p= .004). Both of these findings are concordant with
the findings in the broader regions of 7p and 9p, respectively,
described above.
Past studies have detected associations between distinct genomic
events, and these findings provided insight into either the
underlying biology or the clinical management of cancer patients
[25,26]. In HNSCC, simultaneous CCND1 gains and CDKN2A
losses have been studied by Okami et al. [27] and Namazie et al.
[28], with Namazie et al. detecting an association between these
genomic events. We found that CCND1 CN gains were associated
with CDNK2A losses across all subtypes (Table S7), and that the
joint event was associated with the expression subtypes (Table 2),
thereby confirming and extending the results of Namazie et al.
Molecular Subtypes in Head and Neck Cancer
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Clinical Outcomes by Expression Subtype and Focal
Genomic Alterations
Having parsed the set of nearly 140 HNSCC tumors into
expression subtypes, and in light of known risk factors such as
HPV, smoking, and alcohol use, we considered whether additional
stratification for patient outcomes could be suggested. We first
investigated whether the survival advantage reported by Chung
et al. for ‘‘subtype 10 could be reproduced in the current cohort.
We were unable to confirm this result, and in the current study
there was no association between recurrence-free survival and
tumor subtype, either overall (Figure 4A) or when we restrict to
late stage patients (not shown). These differences may be explained
by the clinical heterogeneity of the disease combined with the fact
that tumor site distributions in the two studies are markedly
different.
In order to clarify whether known or suspected confounders
might have affected our ability to detect subtype-specific
differences in patient outcome, we evaluated the impact of HPV
status on overall survival. We observed a relatively large but
imprecise effect due to the overall small number of HPV+ patients
(Figure 4B). We therefore considered it reasonable to re-evaluate
the cohort with HPV+ patients excluded. Exclusion of HPV+
patients revealed that the AT subgroup demonstrated a particu-
larly unfavorable outcome (Figure 4C), and this difference was
statistically significant when compared to all other subtypes
combined (Figure 4D). We then accessed an independent set of
122 tissue microarray (TMA) samples in an effort to validate this
finding. Because array-based GE and immunohistochemistry
(IHC) staining values are not comparable, it was not feasible to
Figure 2. Copy Number Gains and Losses in the Expression Subtypes. Plots of the mean copy number values in the HNSCC expression
subtypes after smoothing and outlier removal, both genome-wide (A) and for specific chromosomes or regions of interest (B).
doi:10.1371/journal.pone.0056823.g002
Figure 3. Average Gene Expression and Copy Number by
Expression Subtype. Mean gene-specific copy number and gene
expression values in the HNSCC expression subtypes and normal tonsil
samples (NL) for genes in the 3q amplicon.
doi:10.1371/journal.pone.0056823.g003
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predict the tumor subtype of each TMA sample. Instead we used
low EGFR and high p16 staining as a proxy for AT status. The
difference in survival times was not statistically significant, but we
obtained results similar to those described above (Figure S4).
We also investigated whether any focal copy number events
were associated with clinical outcome. Previous studies have
detected a correlation between CCND1 gains and decreased
recurrence-free survival times in HNSCC [29]. We obtained
similar findings when we examined the CN values for all tumor
samples (Figure S5), although our results are marginally significant
(p = .07). Remarkably few AT subjects exhibited CCND1 gains
(Table 2), and this suggests the presence of two largely distinct
groups of patients with poor clinical outcomes: those with CCND1
gains and those that are HPV2 and AT. Figure S6 supports this
conclusion.
Expression Subtypes in Model Systems
The Cancer Cell Line Encyclopedia [30] contains genomic data
from over 900 human cancer cell lines, including both GE and CN
data from 19 esophageal and 18 upper aerodigestive tract cell
lines. We applied our centroid predictor to the GE data from these
cell lines and found that all four expression subtypes were present
(Table S8). These findings are particularly compelling in light of
the clinical relevance of the expression subtypes because they
provide the basis for future studies involving model systems. Figure
S7 provides examples to illustrate that subtype-specific CN events
are also seen in the cell lines.
Discussion
Our primary result was the detection of four gene expression
subtypes in HNSCC – basal, mesenchymal, atypical, and classical.
We also showed that these subtypes have biological and clinical
relevance, and therefore they provide a useful and informative
mechanism of classifying HNSCC tumors that complements
existing methods based on histology and tumor site. Analysis of
publicly available expression datasets revealed that these subtypes
are reproducible in HNSCC [8] and are remarkably similar to
those found in LUSC [7,10]. Although gene expression patterns
for the secretory LUSC subtype are similar to those seen in the
mesenchymal subtype of HNSCC, we favor an alternate
nomenclature. Data confirming the glandular origin of HNSCC
is less compelling compared to that for the lung, and evidence of
a mesenchymal signature is abundant [7]. While it would be
possible to use the existing data to produce a gene predictor for
HPV status, we did not attempt to do this because results of this
nature were presented by Martinez et al. [31]. Regions of
recurrent DNA copy number gain and loss were detected, some
of which contain known oncogenes and tumor suppressors. The
copy number values in certain aberrant regions were associated
with tumor subtype, which suggests that copy number events may
contribute to the development of expression subtypes. All of the
expression subtypes were detected in HNSCC cell lines, a finding
that provides the basis for future studies.
We now briefly discuss the definitions of the expression
subtypes. Basal and classical were chosen because the expression
patterns in these subtypes showed strong similarities to the basal
and classical subtypes of LUSC. Wilkerson et al. compared the
expression patterns in the LUSC subtypes to time course data
from developing human bronchial epithelial cells, and they found
that the basal subtype had similar expression patterns to those seen
at early time points when basal cells are most common. Similarly,
as shown in Table S2, we observed that the basal subtype of
HNSCC is most similar to the day 3 time point in the time course
data from the ALI model [22]. The classical subtype exhibits
canonical genomic alterations associated with squamous cell
carcinoma – e.g. deletion of 3p and 9p, amplification of 3q, and
focal amplification of both EGFR and CCND1. Mesenchymal was
selected based on pathway analysis indicative of an epithelial to
mesenchymal transition. Finally, atypical was chosen because of
the lack of either EGFR amplification or deletion of 9p.
The differences in the expression patterns found in the subtypes
are clinically relevant. TP63 produces six distinct proteins, and
DNp63 is the most abundant isoform in HNSCC [32]. Yang et al.
[33] show that DNp63 promotes cell proliferation. Chatterjee
et al. [32] noted that exposure to cisplatin led to decreased levels
of DNp63, so this treatment may be particularly effective for
patients in BA. Barbieri et al. [34] showed that loss of TP63 in
HNSCC cell lines led to the acquisition of a mesenchymal
phenotype, which is compelling in light of the low expression levels
of TP63 seen in MS. Martin and Cano [35] indicated that elevated
expression of TWIST1 or BMI1 in HNSCC cell lines could
increase the likelihood of invasiveness and migration. Because MS
tumors exhibited an EMT phenotype and increased expression of
Table 2. DNA Copy Number Events Involving Canonical Cancer Genes.
Total Basal Mesenchymal Atypical Classical p-Value
CCND1 Gain .12
No 54 17 14 16 7
Yes 30 9 7 4 10
CDKN2A Loss .004
No 63 20 19 18 6
Yes 21 6 2 2 11
Joint CCND1/CDKN2A Joint Event .068
No 72 23 20 19 10
Yes 12 3 1 1 7
EGFR Gain .069
No 72 22 18 20 12
Yes 12 4 3 0 5
Summaries of focal copy number events for specific genes in the HNSCC expression subtypes.
doi:10.1371/journal.pone.0056823.t002
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both TWIST1 and BMI1, these subjects may be more likely to
develop distant metastases. The fact that EGFR is overexpressed in
the vast majority of HNSCC tumors [36] makes EGFR inhibitors
an attractive treatment option for this disease. However, these
therapies are less likely to be effective in AT tumors because EGFR
expression was lower than in the other expression subtypes. SOX2
and ALDH1 were highly expressed in AT and CL, and both of
these genes are putative cancer stem cell markers because of their
contributions to self-renewal and a pleuripotent phenotype
[37,38]. The protein product of PIK3CA is p110a, which
phosphorylates AKT. Activated AKT contributes to the survival
of tumor cells, and thus oncogenic transformation [39]. West et al.
[40] showed that exposing normal lung epithelial cells to nicotine
facilitates activation of AKT by making it dependent on PI3K
alone. This observation, combined with the high levels of smoking
seen in CL, suggests that PI3 kinase inhibitors provide an
attractive treatment option for CL tumors.
There were several limitations to this study. First, we did not
have GE, CN, and clinical data for all study subjects, which
limited our ability to jointly analyze these variables. In addition,
although the subtype labels were objectively defined by a clustering
algorithm and the gene expression patterns were independently
validated, the clinical associations were not. Copy number arrays
were generated for all samples with sufficient quality and quantity
of DNA. Unfortunately, over 20% of the arrays failed to meet
standardized quality metrics. Also, it was not clear which
isoform(s) of TP63 were assayed by our gene expression arrays,
and unfortunately the role that TP63 plays in the basal subtype
cannot be fully appreciated without knowledge of these isoforms.
Because the HPV+ samples were removed when conducting our
secondary survival analysis, these results should be viewed as
exploratory and thus must be independently validated. Finally, the
HPV status of all patients was not available.
In conclusion, we confirmed four molecular classes of HNSCC
(basal, mesenchymal, atypical, and classical), consistent with
signatures established for squamous carcinoma of the lung. Using
an integrated genomic analysis and validation methodology, we
documented subtypes identified by canonical tumor suppressor
genes and oncogenes, including deregulation of the KEAP1/
NFE2L2 oxidative stress pathway, differential utilization of the
lineage markers SOX2 and TP63, and preference for the
oncogenes PIK3CA and EGFR. For potential clinical use, the
signatures are complimentary to classification by HPV infection
status as well as the putative high risk marker CCND1 copy
number gain. A molecular etiology for the subtypes is suggested by
statistically significant chromosomal gains and losses and differ-
Figure 4. Recurrence-Free Survival in Expression Subtypes. Kaplan-Meier plots and Log-Rank Test p-values comparing recurrence-free
survival times in all expression subtypes (A), HPV+ vs. HPV2 subjects (B), all expression subtypes in HPV2 subjects (C), and AT vs. non-AT in HPV2
subjects (D). Statistical significance was assessed using the Log Rank Test.
doi:10.1371/journal.pone.0056823.g004
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ential cell of origin expression patterns. Model systems represen-
tative of each of the four subtypes were also presented.
Materials and Methods
Tumor Collection and Genetic Assays
After receiving written informed consent, frozen, surgically
extracted, macrodissected head and neck tumors were collected at
the University of North Carolina under Institutional Review
Board protocol #01–1283. Tumor RNA was extracted and
mRNA expression was assayed using Agilent 44K microarrays.
Tumor DNA was extracted and DNA copy number was assayed
using Affymetrix GenomeWide SNP 6.0 chips. A summary of all
genetic data used in this study can be found in Table S9.
mRNA Expression Analysis
Quality control procedures were applied to microarray probe-
level intensity files. A total of 138 tumor arrays remained after
removing low-quality arrays, duplicate arrays, and arrays from
non-HNSCC samples. The normexp background correction and
loess normalization procedures [41] were applied to the probe-
level data. After log2 transformation, probes were matched to
a common gene database to produce expression values for 15597
genes.
Unsupervised Expression Subtype Discovery
The procedure described here is similar to that which appeared
in Wilkerson et al. [7]. After expression values were gene median
centered, gene variability was computed using the median
absolution deviation. The 2500 most variable genes were selected.
ConsensusClusterPlus [12] was used to perform unsupervised
clustering for these genes in the 138 arrays. This procedure was
performed with 1000 randomly selected sets of microarray samples
using a sampling proportion of 80% and a distance metric equal to
one minus the Pearson correlation coefficient.
Statistical Significance of Gene Expression Patterns in
Expression Subtypes
To confirm the statistical significance of four clusters, SigClust
[13] was applied using the set of the 2500 most variable genes
described above. All pairwise comparisons of the subtypes were
examined using 1000 simulated samples and the original co-
variance estimation method.
Differentially Expressed Genes and Metabolic Pathways
Differentially expressed genes were detected with the R package
samr [42] using a median FDR threshold of.01. For each of the
UNC subtypes we compared the gene expression values in the
subtype to all other subtypes combined. DAVID [43] was then
used to find KEGG pathways that showed enrichment for the
highly expressed genes in each subtype. In addition, differentially
expressed genes with known functional categories, e.g. transcrip-
tion factors, were found by comparing the subtype-specific gene
lists to known gene ontology categories [44].
Published Expression Data
The microarray probe-level intensity files produced by Chung
et al. [8] were subjected to background correction, normalization,
and gene-level summarization procedures similar to those de-
scribed above. This produced gene expression values for 60
subjects and 8224 genes. The subtype labels for these 60 arrays
that appeared in [8] are referred to as Chung subtypes 1, 2, 3, and
4.
Summary RPKM values for 20,502 genes and 178 subjects were
obtained based on the RNASeq data presented in [10]. The
RPKM values were log2 transformed, and any gene that contained
at least one missing value was removed from the analysis. This
produced gene expression value for 15,314 genes.
Validation of Expression Subtypes
Consensus clustering assigns a subtype label to every array. As
a result, some arrays may not be representative of their subtype.
Using silhouette widths [45], we identified a set of 125 ‘‘core’’
samples whose expression patterns were more similar to those of
members of their own subtype than other subtypes. ClaNC [46],
a classification method based on nearest centroids, was then
applied to the UNC expression data from the core samples in an
effort to create a set of classifier genes whose expression signature
could be used to classify new samples. Minimizing the cross-
validation error rate produced a list of 840 classifier genes (210
genes per subtype).
We identified the classifier genes whose expression values are
also present in the Chung expression dataset, and then restricted
the UNC and Chung expression datasets to these genes. After gene
median centering each dataset separately, we found the centroid
for each of the UNC and Chung subtypes by computing the
median expression value for each gene over all arrays having the
appropriate subtype label. As in [7], the distances between the
UNC and Chung centroids were computed using a distance metric
equal to one minus the Pearson correlation coefficient. This
validation process was repeated using the LUSC data of Wilkerson
et al. [7]. The RNASeq data from [10] was handled similarly with
the following differences: (i) gene expression values from the UNC
and log2(RPKM) values from the TCGA datasets were separately
median centered and standardized by gene, (ii) predicted class
labels were found, but class centroids were not computed.
DNA Copy Number Analysis
CEL files were subjected to quality control procedures using the
Affymetrix Genotyping Console, and arrays that produced
contrast QC measurements above the default threshold of.4 were
removed from subsequent analyses. The intensity values in the
CEL files were then converted to log2 copy number values using
the R package aroma [47] and a pooled collection of normal
samples. A total of 107 arrays remained after manually reviewing
the genome-wide copy number profiles, 84 of which have
expression subtype labels. Missing values were imputed using the
non-missing value from the closest probe. Segmentation was
performed using DNAcopy [48].
Recurrent copy number gains and losses were detected with
DiNAMIC [49] after smoothing and median centering the copy
number profiles, as was done in [11]. DiNAMIC p-values were
computed using 250 cyclic shifts, and gains and losses were
classified as statistically significant if resulting p-values were less
than.05. Regions harboring recurrent CN gains and losses were
found using the bootstrap confidence interval procedure at level.95
with 500 bootstrap samples.
Associations between expression subtype and the five most
significant gain and loss events were assessed as in [11]. First, for
each subject the mean CN value over the corresponding
confidence interval was computed. This was done with the
smoothed and median centered CN values that were used to
compute the confidence intervals, as described above. Then
Kruskal-Wallis tests were applied to assess the association between
each subject’s mean CN value and the expression subtype labels.
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Copy Number Gains and Losses of Canonical Cancer
Genes
The gene-specific copy number was determined by computing
the mean of all segmented copy number values at probes lying
within or immediately adjacent to the gene. For each subject we
classified a gene as having a copy number gain (loss) if the gene-
specific copy number was above.35 (below 2.35), which is
approximately two standard deviations above (below) the mean
of all segmented copy number values.
Assessing HPV Status
Human papillomavirus was assessed using in situ hybridization.
Slide deparaffinization, conditioning, and staining with INFORM
HPV III Family 16 Probe (B; Ventana Medical Systems) were
done on the Ventana Benchmark XT Autostainer according to the
manufacturer’s protocol. The probes have affinities to HPV
genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66. Slides
were scored as positive for HPV if a punctuate or diffuse pattern of
signal were observed in the tumor nuclei.
Statistical Analysis
R-2.12.2 and R-2.15.1 were used to perform all data analyses
and create all figures. The statistical significance of associations
between all categorical variables was assessed with Fisher’s Exact
Test or a Monte Carlo version of Fisher’s Exact Test (p-values
include an asterisk). Kruskal-Wallis tests were used to assess the
statistical significance of associations of continuous variables with
the expression subtypes. The survival package [50] was used to
perform all survival analyses, and all p-values were computed
using the log rank test. Recurrence-free survival (RFS) time was
defined to be the time in months from tumor biopsy to death,
recurrence, or loss to follow-up. Complete clinical data for all
subjects, including RFS time, is presented in Table S10.
Chromosomal Instability Index
For a given subject, we computed the median of the absolute
value of the smoothed, segmented copy number values in each
chromosome arm. The median of the arm-specific medians was
defined to be the chromosomal instability index, which is similar to
the definition that appears in [11].
Cancer Cell Line Data
CN and GE data are available for 18 esophagus and 19 upper
aerodigestive tract cell lines that were classified as squamous cell
carcinoma in the Cancer Cell Line Encyclopedia [30]. GE data in
the cell lines are available for 803 of the 840 genes in our classifier.
After restricting to these common genes, we normalized the GE
data for the cell lines so that it had the same gene-specific means
and standard deviations as in our classifier. We then used the
centroid-based method described above to predict expression
subtypes for the cell lines.
Data Availability
GE, CN, and select clinical data are available from GEO
(accession number GSE39368).
Supporting Information
Figure S1 Evidence Supporting the Presence of Four
Expression Subtypes. Results are produced by Consensu-
sClusterPlus for 138 subjects and the 2500 most variable genes. (A)
Heatmap of the consensus matrix for k = 4 clusters. Entries in the
consensus matrix measure the proportion of times two samples
occur in the same cluster. High values (dark blue) show samples
that are highly similar. (B) Plot of consensus cumulative
distribution functions (CDFs) for different numbers of clusters k.
Large differences between k= 2 (red), k = 3 (yellow), and k= 4
(green) shows greater stability with increasing numbers of clusters.
Increasing k beyond 4 produces small gains. (C) The tracking plot
shows that large numbers of samples change cluster label for k= 2,
k = 3, and k= 4, indicating unstable clusters. However, only a small
number of subjects change class between k= 4 and k= 5. (D)
Bonferroni-adjusted SigClust p-values are highly significant (6
tests), indicating that all pairwise comparisons of the gene
expression patterns in the four clusters are statistically significantly
different.
(TIF)
Figure S2 Expression Subtypes in HNSCC and LUSC.
Gene expression heatmap for the 715 of the 840 HNSCC from the
current study (A) and the TCGA LUSC data (B). Strong
similarities are seen between CL in both tumor types as well as
MS in HNSCC and SE of LUSC. Gene expression heatmap for
a representative set of genes known or suspected to be relevant for
head and neck cancer from the core samples (C) and the TCGA
LUSC data (D).
(TIF)
Figure S3 Chromosomal Instability Index by Expres-
sion Subtype. Boxplots of chromosomal instability indices in
each of the gene expression subtypes as well as normal tonsil
samples (NL).
(TIF)
Figure S4 Kaplan-Meier Curves for HPV- Tissue Micro-
array Samples. Kaplan-Meier curves illustrating differences in
recurrence-free survival times for tissue microarray samples based
on HPV status and immunohistochemical staining group (EGFR
low/p16 high vs. others). Statistical significance was assessed using
the log rank test.
(TIF)
Figure S5 Kaplan-Meier Curves for CCND1 Copy
Number Gains. Kaplan-Meier curves illustrating differences in
recurrence-free survival times for subjects with and without
CCND1 copy number gains. Statistical significance was assessed
using the log rank test.
(TIF)
Figure S6 Kaplan-Meier Curves Illustrating Two
Groups with Poor Survival Outcomes. Kaplan-Meier curves
illustrating differences in recurrence-free survival times for four
mutually exclusive groups of patients: (1) HPV+ subjects (HPV+),
(2) HPV2 patients with CCND1 gains (CCND1 Gain), (3) HPV2
patients without CCND1 gains that are AT (HPV2 AT), (4) all
remaining patients (Other). Statistical significance was assessed
using the log rank test.
(TIF)
Figure S7 Copy Number Plots from the Cancer Cell
Line Encyclopedia Data. Copy number plots show that
genomic events detected in the UNC HNSCC cohort can also
be found in the HNSCC cell lines from the Cancer Cell Line
Encyclopedia. A. Amplifications in chromosome 3q are seen in all
predicted subtypes, and the predicted classical subtype exhibits
focal amplification of the region containing SOX2. B. SCC15
(predicted basal) exhibits focal amplification of EGFR, while
HS840T (predicted atypical) has normal copy number. C. Both
KYSE140 (predicted mesenchymal) and KYSE70 (predicted
classical) exhibit focal deletion of CDKN2A. D. Both FADU
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(predicted mesenchymal) and SCC15 (predicted basal) exhibit
focal amplification of CCND1. Note that gains of 11q22 are also
seen for SCC15.
(TIF)
Table S1 Differentially Expressed Genes in the Expres-
sion Subtypes. The R package samr was used to identify genes
that were differentially expressed when each subtype was
compared to all other subtypes combined based on an FDR
threshold of q= .01.
(XLSX)
Table S2 Biological Characteristics of Expression Sub-
types. Table S1 lists genes that were differentially expressed when
each subtype was compared to all other subtypes combined.
Biological characteristics and molecular pathways representative
of the highly expressed genes were then identified, as were other
relevant genes (e.g. growth/transcription factors).
(DOCX)
Table S3 Comparison of Expression Patterns in the
Expression Subtypes and Time Course Data from the
Air Liquid Interface Model. Correlation-based distances
between class centroids for the expression subtypes and time
course centroids for the air liquid interface model show that the
most similar expression subtype changes over time, with basal
being the most similar at Day 3. Distance is equal to 1 minus the
Pearson correlation coefficient of the centroids of interest.
(DOCX)
Table S4 Regions Exhibiting Recurrent Copy Number
Gain and Loss Events. DiNAMIC was used to assess the
statistical significance of recurrent copy number gain and loss
events. Confidence intervals for the copy number events were also
computed. For each event, ‘‘Marker’’ refers to the most significant
copy number locus, while ‘‘Left’’ and ‘‘Right’’ refer to the
boundaries of the associated confidence interval. Positions are
hg18 genomic coordinates.
(XLSX)
Table S5 Expression Subtypes Exhibit Different Copy
Number Patterns in Regions of Chromosomal Gain and
Loss. Unadjusted Kruskal-Wallis Test p-values are given for
associations between expression subtype and subject-specific mean
copy numbers in the confidence intervals containing the five most
significant gain and loss events. Adjusted p-values were computed
using a Bonferroni adjustment (ten tests).
(DOCX)
Table S6 Expression Subtypes Exhibit Different Ex-
pression Patterns of Oncogenes in Chromosome 3q.
Unadjusted Kruskal-Wallis Test p-values are given for associations
between subject-specific expression of TP63, PIK3CA, and SOX2
and expression subtype. Adjusted p-values were computed using
a Bonferroni adjustment (three tests).
(DOCX)
Table S7 Overall Association of CCND1 Gains and
CDKN2A Losses. Two-by-two table illustrating CCND1 gains
and CDKN2A losses, together with Fisher’s Exact Test p-value.
(DOCX)
Table S8 Predicted Expression Subtypes in Head and
Neck Cancer Cell Lines. Predicted gene expression subtypes in
head and neck cancer samples of the Cancer Cell Line
Encyclopedia obtained using the centroid predictor described in
Methods.
(DOCX)
Table S9 Summary of Datasets. Summary of data and tissue
types, sample sizes, and platforms for all datasets discussed herein.
(DOCX)
Table S10 Clinical Data by Subject. Clinical data for each
of the 138 subjects that have expression subtypes.
(XLSX)
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